Results for “Amgen”

…ult in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent for patients with heterozygous familial hypercholesterolemia, a genetic condition that...

…ult in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent for patients with heterozygous familial hypercholesterolemia, a genetic condition that...

…ult in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent for patients with heterozygous familial hypercholesterolemia, a genetic condition that...

who is conducting a clinical trial Amgen and Pfizer

…oard observer status with Labcyte. Vijay was previously on the boards of Advanced Cell Diagnostics, Ilypsa (acquired by Amgen) and Relypsa (NASDAQ: RLYP). Prior to joining Sprout, Vijay spent one year as an analyst in the healthcare venture capital group at Robertson Stephens whe...

…E ACCOUNT - HOLDINGS 1 ALTRIA GROUP INC NIA None (or less than $1 ,001) Dividends.Capital Gain $100,001 - $1 ,000,000 2 AMGEN INC NIA None (or less than $1 ,001) Dividends.Capital Gain $50,001 - $100,000 Information being reported is as of April 15, 2017. OGE FolTll 278e (March 2...

…ystems, Inc. NetApp, Inc. QUALCOMM Incorporated Apple Inc. Juniper Networks, Inc. Symantec Corporation PVH Corp. Amgen Inc. General Electric Company Microsoft Corporation Teradata Corporation Cognizant Technology Solutions Corp. Class A Ralph Lauren Corporation Class A...

because Amgen and Regeneron will compete by giving the insurers rebates.

…rate companies), Durata Therapeutics (NLV-II: IPO - July, 2012, NASDAQ: DRTX), and Ilypsa (Sprout IX, exited in sale to Amgen, 6.9x multiple). e Established Private Companies: The New Leaf Team has played the role of lead investor in a large number of private investments. These...

…oard observer status with Labcyte. Vijay was previously on the boards of Advanced Cell Diagnostics, Ilypsa (acquired by Amgen) and Relypsa (NASDAQ: RLYP). Prior to joining Sprout, Vijay spent one year as an analyst in the healthcare venture capital group at Robertson Stephens whe...

…nvey Mount Sinai’s research capabilities. These efforts attracted ongoing contracts from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. She facilitated over $18 million in grant funding, increased clinical trials by 40% and grew pa...

…f first refusal in phase III clinical trials (with appropriate patient populations) from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. • Grew research revenue by increasing clinical trials by 40% and patient enrollment by over 320...

…nvey Mount Sinai’s research capabilities. These efforts attracted ongoing contracts from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. She facilitated over $18 million in grant funding, increased clinical trials by 40% and grew pa...